ClinicalTrials.Veeva

Menu

Acute Coronary Syndrome in Patients With COVID-19 (ACS-COVID)

B

Bulgarian Cardiac Institute

Status

Completed

Conditions

COVID-19
Acute Coronary Syndrome
Myocardium; Injury
Myocardial Infarction

Treatments

Procedure: Coronary angiography

Study type

Observational

Funder types

NETWORK

Identifiers

Details and patient eligibility

About

The aim of this study was to find a clinical or laboratory parameter, that would help in distinguishing between COVID-19 patients with myocardial infarction (MI), who have an infarct-related artery (IRA) and therefore, require immediate revascularization, and those, who have no IRA.

Full description

The coronavirus pandemic has hit the world with its vast contagiousness, high morbidity, and mortality Apart from the direct damage to the lung tissue, the corona virus infection is associated with multiple organ damage, including the heart. Emerging evidence reveals a direct correlation between COVID-19 and cardiovascular complications, such as heart failure, myocarditis, arrhythmias, conduction abnormalities and acute coronary syndromes. The SARS-CoV-2 infection can frequently induce coagulation abnormalities that are associated with cardiopulmonary deterioration and death as a possible complication in all patients, despite presence or absence of concomitant risk factors and diseases. In addition, many patients with severe COVID-19 undergo thromboembolic events, which seem to be related to this particular coagulopathy. One of the most unpleasant and life-threatening types of thromboembolism is the one involving the coronary circulation, thus causing a heart attack. Many additional problems arise due to this condition e.g., access to a Cath lab, exposure of additional medical personnel, more complications and increased mortality for the patients.

Invasive angiography for COVID-19 patients is logistically challenging and, in some cases, there is no intervention target, since microcirculatory disease and thrombosis is common in this group. Therefore, the investigators studied in detail the case series of 10 patients referred for primary percutaneous coronary intervention (pPCI) for MI in our catheterization laboratory during the course of COVID-19 infection. And the investigators set themselves the purpose to evaluate if there are some factors or parameters that could predict the presence of an interventional target - infarct related artery (IRA), prior to catheterization, and to determine their sensitivity and specificity.

Enrollment

26 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Acute coronary syndrome (ACS)
  • COVID-19 infection

Exclusion criteria

  • No combination of ACS and COVID-19 infection

Trial design

26 participants in 2 patient groups

Patients with ACS and no IRA
Description:
Patients with acute coronary syndrome (ACS) during a COVID-19 infection, who after undergoing coronary angiography - no infarct-related artery (IRA) is found
Treatment:
Procedure: Coronary angiography
Patients with ACS and IRA
Description:
Patients with acute coronary syndrome (ACS) during a COVID-19 infection, who after undergoing coronary angiography - an infarct-related artery (IRA) is found
Treatment:
Procedure: Coronary angiography

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems